ALX ONCOLOGY HOLDINGS INC
ALXO · XNASCIK 1810182fmd_1D9MJDM8R58D5QSWV8CWXW3TAZManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2018 to Jun 30, 2026, 31 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 5 | 1 | 0 | 0 | – | – | – |
| Research and development | 11 | 16 | 29 | 60 | 98 | 142 | 116 | 77 |
| Total operating expenses | 16 | 24 | 45 | 84 | 127 | 170 | 142 | 104 |
| Operating income | (14) | (19) | (44) | (84) | (127) | (170) | (142) | (104) |
| Interest expense | – | – | – | 0 | 0 | 2 | 2 | 2 |
| Interest and investment income | – | – | – | 0 | 4 | 11 | 9 | 4 |
| Other non-operating income (expense) | – | (0) | (1) | (0) | (0) | 0 | (0) | (0) |
| Income before taxes | (14) | (19) | (45) | (83) | (123) | (161) | (135) | (102) |
| Income tax expense | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (14) | (19) | (46) | (83) | (123) | (161) | (135) | (102) |
| Net income | (14) | (19) | (46) | (83) | (123) | (161) | (135) | (102) |
| Net income to common shareholders | (17) | (23) | (51) | (83) | (123) | – | – | – |